Cargando…
Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study
Somatostatin analogs (SSAs), including lanreotide, play a fundamental role in treatment of neuroendocrine tumors (NETs) of the gastrointestinal tract. SSAs control the clinical symptoms and are the treatment of choice in functioning NETs. Data indicating that SSAs have anti-proliferative activity ha...
Autor principal: | Kos-Kudła, Beata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709401/ https://www.ncbi.nlm.nih.gov/pubmed/26793016 http://dx.doi.org/10.5114/wo.2015.56006 |
Ejemplares similares
-
Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017) -
The Risk of Venous Thromboembolism in Neuroendocrine Neoplasms
por: Wójcik-Giertuga, Monika, et al.
Publicado: (2023) -
LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis
por: Orlewska, Ewa, et al.
Publicado: (2014) -
The clarinet and clarinet playing
por: Pino, David
Publicado: (1998) -
Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
por: Rosiek, Violetta, et al.
Publicado: (2023)